Locally enhanced chemotherapy by electroporation: Clinical experiences and perspective of use of electrochemotherapy

Ruggero Cadossi, Mattia Ronchetti, Matteo Cadossi

Research output: Contribution to journalArticlepeer-review


Electroporation is used to enhance drug diffusion and gene delivery into the cytosol. The combination of electroporation and cytotoxic drugs, electrochemotherapy (ECT), is used to treat metastatic tumor nodules located at the skin and subcutaneous tissue. The objective response rate following a single session of treatment exceeds 80%, with minimal toxicity for the patients. The efficacy of ECT in the bone and visceral metastasis is currently investigated, and Phase II studies have been completed. ECT has been used to treat skin primary tumors, except melanoma, and is under investigation for locally advanced pancreatic cancer. Early evidence suggests that treatment of tumor nodules with ECT recruits components of the immune system and eliciting a systemic immune response against cancer is a challenging clinical perspective. Considering the proven safety in several different clinical applications electroporation should be viewed as a clinical platform technology with wide perspectives for use in ECT, gene therapy and DNA vaccination.

Original languageEnglish
Pages (from-to)877-890
Number of pages14
JournalFuture Oncology
Issue number5
Publication statusPublished - 2014


  • bleomycin
  • cancer
  • cisplatin
  • Cliniporator™
  • electrochemotherapy
  • electroporation
  • gene therapy
  • melanoma
  • metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)


Dive into the research topics of 'Locally enhanced chemotherapy by electroporation: Clinical experiences and perspective of use of electrochemotherapy'. Together they form a unique fingerprint.

Cite this